Skip to main content
. Author manuscript; available in PMC: 2015 May 1.
Published in final edited form as: J Neurochem. 2014 Feb 7;129(4):721–731. doi: 10.1111/jnc.12653

Figure 1. Measuring nAChR binding sites after 2-phase chronic treatments.

Figure 1

(A) Male mice and rats underwent a 2-phase drug treatment paradigm as illustrated in the figure. Saline (Sal) and drugs were delivered by osmotic minipumps at the following doses (free base): Rats; 6 mg/kg/day nicotine (Nic), 4.7 mg/kg/day saz-A, and 1.2 mg/kg/day varenicline (Var). Mice; 18 mg/kg/day nicotine; 1.8 mg/kg/day saz-A; and 1.8 mg/kg/day varenicline. For rats, osmotic minipumps were removed following the completion of phase 2 treatments to allow drug elimination and were sacrificed 2 days later. Mice were sacrificed while pumps were still implanted following completion of phase-2 treatments. The density of nAChR binding sites were measured in cortical membrane homogenates from both (B) rats and (C) mice using 2 nM [3H]EB. These densities were graphed as the mean ± SEM from 4 – 8 animals in each group. Statistical analysis was compared to Sal→Sal treatments by a one-way ANOVA with a post-hoc Bonferroni test (ns = not significant; **p<0.01; ***p<0.001).